Literature DB >> 30108808

2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors.

A V Subba Rao1,2, Bala Bhaskara Rao2,3, Satish Sunkari1,2, Siddiq Pasha Shaik1,2, Bajee Shaik1, Ahmed Kamal1,2.   

Abstract

A new series of 2-arylaminobenzothiazole-arylpropenone conjugates 5-6(a-r) was designed, synthesized and investigated for their cytotoxic potency against the various human cancer cell lines. Most of these conjugates exhibited cytotoxic activity and inhibited in vitro tubulin polymerization effectively. Conjugates 5d and 6d cause cell cycle blocks in the G2/M phase in HeLa cells and treatments with 5d and 6d manifested increased mRNA and protein levels of the G2/M marker, cyclin B1. Immunocytochemistry revealed loss of intact microtubule structure in cells treated with 5d and 6d. Western blot analysis revealed that these conjugates accumulate more tubulin in the soluble fraction. Moreover, the triggering of apoptotic cell death after mitotic arrest was investigated by studying their effect on Hoechst staining, mitochondrial membrane potential, ROS generation.

Entities:  

Year:  2017        PMID: 30108808      PMCID: PMC6071745          DOI: 10.1039/c6md00562d

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  34 in total

Review 1.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro.

Authors:  R J Vasquez; B Howell; A M Yvon; P Wadsworth; L Cassimeris
Journal:  Mol Biol Cell       Date:  1997-06       Impact factor: 4.138

Review 3.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

Review 4.  Paclitaxel in cancer therapy.

Authors:  Tarek M Mekhail; Maurie Markman
Journal:  Expert Opin Pharmacother       Date:  2002-06       Impact factor: 3.889

Review 5.  The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.

Authors:  E K Rowinsky; R C Donehower
Journal:  Pharmacol Ther       Date:  1991-10       Impact factor: 12.310

6.  In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.

Authors:  Chee Onn Leong; Marie Suggitt; David J Swaine; Michael C Bibby; Malcolm F G Stevens; Tracey D Bradshaw
Journal:  Mol Cancer Ther       Date:  2004-12       Impact factor: 6.261

7.  Novel cyano- and amidinobenzothiazole derivatives: synthesis, antitumor evaluation, and X-ray and quantitative structure-activity relationship (QSAR) analysis.

Authors:  Irena Caleta; Marijeta Kralj; Marko Marjanović; Branimir Bertosa; Sanja Tomić; Gordana Pavlović; Kresimir Pavelić; Grace Karminski-Zamola
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

Review 8.  Cytochrome P450 enzymes: novel options for cancer therapeutics.

Authors:  Morag C E McFadyen; William T Melvin; Graeme I Murray
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

Review 9.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

10.  Cell cycle-dependent regulation of the cyclin B1 promoter.

Authors:  A Hwang; A Maity; W G McKenna; R J Muschel
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

View more
  1 in total

Review 1.  Synthetic Approaches to Biologically Active C-2-Substituted Benzothiazoles.

Authors:  Bagrat A Shainyan; Larisa V Zhilitskaya; Nina O Yarosh
Journal:  Molecules       Date:  2022-04-18       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.